Chloropyramine hydrochloride

C[where?] D04AA09(WHO)R06AC03(WHO) By mouth:OTC, Injection: Rx-only(RU) N'-[(4-chlorophenyl)methyl]-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine 59-32-5Y 25295 DB08800Y 23628Y 2K3L8O9SOV D07195Y ChEMBL1194287N DTXSID50207729 Interactive image Clc1ccc(cc1)CN(c2ncccc2)CCN(C)C InChI=1S/C16H20ClN3/c1-19(2)11-12-20(16-5-3-4-10-18-16)13-14-6-8-15(17)9-7-14/h3-10H,11-13H2,1-2H3YKey:ICKFFNBDFNZJSX-UHFFFAOYSA-NY Chloropyramineis a first-generationantihistaminedrug approved in several Eastern European countries such as Russia for the treatment ofallergic conjunctivitis,allergic rhinitis,bronchial asthma, and otheratopic(allergic) conditions.​​​‍​​‍​​​​‍​​‍‍ Related indications for clinical use includeangioedema, allergic reactions to insect bites, food and drug allergies, andanaphylactic shock. Chloropyramine is known as a competitive reversibleH1receptorantagonist (also known as an H1inverse agonist), meaning that it exerts its pharmacological action by competing withhistaminefor the H1subtype histamine receptor. By blocking the effects of histamine, the drug inhibits the vasodilation, increased vascular permeability, and tissue edema associated with histamine release in the tissue. The H1antagonistic properties of chloropyramine can be used by researchers for the purposes of blocking the effects ofhistamineon cells and tissues. In addition, chloropyramine has someanticholinergicproperties. Chloropyramine's anticholinergic properties and the fact that it can pass through theblood–brain barrierare linked to its clinical side effects such asdrowsiness,weakness,vertigo,fatigue,dry mouth,constipation, and rarely — visual disturbances and increase ofintraocular pressure.